The FDA is scheduled to announce these two key approval decisions in late November.
Compare JNJ Stock to Peers
|Symbol||Last Price||Market Cap||% Δ 1 Yr||% Δ 5 Yr|
Johnson & Johnson
News & Analysis: Johnson & Johnson
The company just got some good news from health authorities.
Investing gets simple if you have to put all of your eggs in one basket.
There's more to the story than the healthcare giant's revenue and earnings numbers.
The healthcare giant recorded healthy growth in all three of its business segments and raised its guidance.
At least initially. It could be a different story over the longer term.
This vaccine could come from its candidate that prevents a little-known respiratory virus.
J&J has set a high bar for its rivals.
They're resilient and already offer attractive dividends.
It's highly likely.